BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36857852)

  • 1. Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer.
    Júnior RFA; Lira GA; Schomann T; Cavalcante RS; Vilar NF; de Paula RCM; Gomes RF; Chung CK; Jorquera-Cordero C; Vepris O; Chan AB; Cruz LJ
    Transl Oncol; 2023 May; 31():101647. PubMed ID: 36857852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
    Cavalcante RS; Ishikawa U; Silva ES; Silva-Júnior AA; Araújo AA; Cruz LJ; Chan AB; de Araújo Júnior RF
    Br J Pharmacol; 2021 Jun; 178(11):2284-2304. PubMed ID: 33434950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea.
    de Carvalho TG; Lara P; Jorquera-Cordero C; Aragão CFS; de Santana Oliveira A; Garcia VB; de Paiva Souza SV; Schomann T; Soares LAL; da Matta Guedes PM; de Araújo Júnior RF
    Biomed Pharmacother; 2023 Dec; 168():115663. PubMed ID: 37832408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer.
    Wang S; Kuai Y; Lin S; Li L; Gu Q; Zhang X; Li X; He Y; Chen S; Xia X; Ruan Z; Lin C; Ding Y; Zhang Q; Qi C; Li J; He X; Pathak JL; Zhou W; Liu S; Wang L; Zheng L
    BMC Med; 2023 Mar; 21(1):115. PubMed ID: 36978108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
    JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
    Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feed-forward loop based on aerobic glycolysis and TGF-β between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape.
    Shen C; Liu J; Jiao W; Zhang X; Zhao X; Yang X; Wang Y
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):12867-12880. PubMed ID: 37462772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
    Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
    J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes.
    Bi S; Huang W; Chen S; Huang C; Li C; Guo Z; Yang J; Zhu J; Song L; Yu R
    Int J Biol Macromol; 2020 May; 150():261-280. PubMed ID: 32044366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceramide and palmitic acid inhibit macrophage-mediated epithelial-mesenchymal transition in colorectal cancer.
    de Araujo Junior RF; Eich C; Jorquera C; Schomann T; Baldazzi F; Chan AB; Cruz LJ
    Mol Cell Biochem; 2020 May; 468(1-2):153-168. PubMed ID: 32222879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
    Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
    J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation.
    Yu Y; Liang Y; Xie F; Zhang Z; Zhang P; Zhao X; Zhang Z; Liang Z; Li D; Wang L; Chen Y; Sun L; Niu H; Wang Y
    Cancer Lett; 2024 May; 593():216964. PubMed ID: 38762193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
    Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
    Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGFβ signaling to facilitate PD-L1 expression in M2-like TAMs.
    Du XX; He C; Lu X; Guo YL; Chen ZH; Cai LJ
    Exp Cell Res; 2021 Aug; 405(2):112655. PubMed ID: 34044017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour microenvironment: a non-negligible driver for epithelial-mesenchymal transition in colorectal cancer.
    Han L; Wang S; Wei C; Fang Y; Huang S; Yin T; Xiong B; Yang C
    Expert Rev Mol Med; 2021 Nov; 23():e16. PubMed ID: 34758892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.